[{"address1": "16 Abba Hillel Road", "city": "Ramat Gan", "zip": "5250608", "country": "Israel", "phone": "972 3 693 8448", "website": "https://www.galmedpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Mr. Allen  Baharaff", "age": 58, "title": "Co-Founder, President, CEO & Chairman", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 972158, "exercisedValue": 0, "unexercisedValue": 1834}, {"maxAge": 1, "name": "Mr. Doron  Cohen", "age": 56, "title": "Chief Financial Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 245982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guy  Nehemya", "age": 38, "title": "COO & Data Protection Officer", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 287036, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yohai  Stenzler CPA", "age": 40, "title": "Chief Accounting Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 290568, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Liat  Hayardeny", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 47934, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tali  Gorfine", "age": 53, "title": "Medical Consultant", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 202763, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.9, "open": 9.0, "dayLow": 7.9011, "dayHigh": 13.58, "regularMarketPreviousClose": 6.9, "regularMarketOpen": 9.0, "regularMarketDayLow": 7.9011, "regularMarketDayHigh": 13.58, "beta": 0.678, "forwardPE": -8.155339, "volume": 36147565, "regularMarketVolume": 36147565, "averageVolume": 2312470, "averageVolume10days": 14284080, "averageDailyVolume10Day": 14284080, "bid": 8.16, "ask": 10.7, "bidSize": 100, "askSize": 900, "marketCap": 5407424, "fiftyTwoWeekLow": 2.73, "fiftyTwoWeekHigh": 23.8, "fiftyDayAverage": 3.99236, "twoHundredDayAverage": 4.32053, "currency": "USD", "enterpriseValue": -5371882, "floatShares": 513945, "sharesOutstanding": 643741, "sharesShort": 40640, "sharesShortPriorMonth": 853, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.0631, "heldPercentInsiders": 0.0301, "heldPercentInstitutions": 0.05408, "shortRatio": 0.42, "shortPercentOfFloat": 0.0648, "impliedSharesOutstanding": 643741, "bookValue": 22.244, "priceToBook": 0.3776299, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -5883000, "trailingEps": -10.44, "forwardEps": -1.03, "lastSplitFactor": "1:12", "lastSplitDate": 1724976000, "enterpriseToEbitda": 0.874, "52WeekChange": 0.111111164, "SandP52WeekChange": 0.32258344, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GLMD", "underlyingSymbol": "GLMD", "shortName": "Galmed Pharmaceuticals Ltd.", "longName": "Galmed Pharmaceuticals Ltd.", "firstTradeDateEpochUtc": 1394717400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ade4d27e-0850-308a-ae7b-98b5c772bca9", "messageBoardId": "finmb_114779940", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.4, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 9823000, "totalCashPerShare": 18.538, "ebitda": -6145000, "quickRatio": 6.408, "currentRatio": 6.484, "returnOnAssets": -0.29313, "returnOnEquity": -0.52666, "freeCashflow": -4066250, "operatingCashflow": -5922000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-20"}]